Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Budgeting for Clinical Research
RFA Title: Antimicrobial Use & Resistance Data Collection (U01)
RFA Number: RFA-FD-16-046
Purpose of the RFA:
The purpose of this RFA is to "support the collection of data on antimicrobial use in animal agriculture. There are two main objectives. The first is to "provide needed information on antimicrobial practices in various animal production settings" and the second is to "provide important information on data collection methodologies to help optimize the long-term strategies for collecting and reporting such data."
Why you selected this particular RFA:
This RFA appealed because of my interest in the subject of antibiotic resistance. This topic felt close to that. Because this RFA concerns antimicrobials use in animals, I felt that it reflected on this subject strongly.
Total Budget: $1.2 million
Budget (Time) Period: 4 years
Budget Categories
Budget Category: Personnel
Estimated Dollar Amount: $800,000
Description of the Category: Key research personnel and support staff
2. Budget Category: Services
Estimated Dollar Amount: $150,000
Description of the Category: This covers lab costs, transportation, and shipping fees, among other services that will be used for this project.
3. Budget Category: Supplies
Estimated Dollar Amount: $50,000
Description of the Category: Lab supplies, computers and communications...
Budget Category: Data capturing mechanism
Estimated Dollar Amount: $20,000
Description of the Category: For this project, surveys will be used to assess the adoption of FDA guidelines, to assess the success of these efforts and to examine the associations between antibiotic use practices and resistance. Many costs associated with data collection -- personnel and supplies -- are in other budget categories, so this category consists mainly of sundries associated with the life of this project.
5. Budget Category: Facilities
Estimated Dollar Amount: $180,000
Description of the Category: This amount is for the use of pre-existing facilities, and for the upgrades that will be needed for this project. There will also be upgrades to facilities to help with the remote collection of data and its processing.
6. Indirect costs not covered by the RFA: There are some indirect costs, such as taxation and possibly some benefits, that might not be covered. Per diems for meals when researchers are on the road may be accrued. The total amount of indirect costs is not expected to be substantial, and will be covered via other means.
References
Wilenberg, K. (2004). Managing clinical trials -- frustration or bliss? Journal of Oncology Management. Nov/Dec 2004, 24-26
Stoller, S. (2009). An introduction to clinical trial budgeting and negotiating. Unpublished. In possession of the author.
Antibiotic resistant organisms has become a topic of much debate in recent years. Antibiotic resistance is a serious concern because of the health care implications that occur as a result of this problem. The purpose of this discussion is to explain antibiotic resistance development in humans. The research will also provide a General overview of specific strains, causes and effects. Antibiotic Resistance Development According to the Centers for Disease Control and Prevention
Conventional approaches including bacterial therapy are becoming less effective and in some cases completely ineffective for combating bacterial infection. Bacteria are evolving, becoming smarter and more virulent, and increasingly resistant to traditional treatment including antibiotic use. While scan the literature available on probiotic use supports use of probiotics for treating drug resistant strains of bacteria in some cases (Diped, 2003). If nothing else the literature supports the use of
Macrolide: Erythromycin This is a proposal describing a study to test the hypothesis that: The macrolide, erythromycin, normally used to treat individuals with community-acquired pneumonia, causes significant antibiotic resistance in patients in Europe but not individuals in the United States. 9 sources To assess the prevalence of macrolide resistance (Erythromycin) among pneumococci in Europe and the United States and difference in frequency of Erythromycin use in both countries for respiratory infections. To
Efficiency of Antibiotic Resistance Gene Transfer Mechanisms Upon Exposure to Triclosan Triclosan has become the latest buzz word in the grocery store. It is being hailed as the ultimate biocide and finds its way into many everyday products such as toothpaste and hand soap. Mass media produced a great amount of hype and convinced the general public that this was necessary to protect them from potentially harmful or even fatal bacteria.
One organism, Methicillin-resistant Staphylococcus aureus (MRSA), kills approximately 19,000 Americans annually, which is more than HIV / AIDS, Parkinson's disease, emphysema, and homicide combined (5). In the mid-1980s, the incidence of MRSA isolates was close to zero, and by 1998 the incidence of MRSA was approximately 70% in Japan, 40% in Belgium, 30% in the United Kingdom, and 28% in the United States (1). Every year, 2 million Americans
Antibiotic Resistant Streptococci There are more than thirty different species of streptococcal bacteria. The infections that strep causes in humans range from "strep throat," which is caused by Group A strep and relatively easily treatable, to diseases such as pneumonia and serious wound infections, both of which can prove deadly.(1) Antibiotics were first developed during World War II, and have saved many millions of human lives since then that would have been